UBS analyst Ashwani Verma lowered the firm’s price target on Coherus Biosciences (CHRS) to $1.05 from $1.50 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Biosciences CCO Resigns After UDENYCA Divestiture
- Coherus Biosciences Completes UDENYCA Franchise Divestiture
- Coherus Biosciences completes divestiture of UDENYCA franchise
- Coherus Biosciences announces repurchase of $170M of convertible notes
- Biotech Alert: Searches spiking for these stocks today